Left ventricular hypertrophy and risk factors for its development in uraemic patients

Rašić, Senija; Kulenović, Indira; Haracić, Azra; Catovic, Amra

doi:10.17305/bjbms.2004.3458

Cited by 13 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of CKD and end-stage renal disease (ESRD) leads to cardiac remodeling with hypertrophy, fibrosis and capillary loss [13]. Uremic cardiomyopathy affects about 80% of hemodialysis patients [14] and is the main cause of death in this cohort. A similar prevalence has even been reported in pediatric uremic patients [15] who presumably lack traditional atherosclerotic risk factors.…”

Section: Pathology and Pathophysiology Of The Cardiorenal Syndromementioning

confidence: 99%

Cardiac Remodeling in Chronic Kidney Disease

Kaesler

Babler

Floege

et al. 2020

Toxins

100

View full text Add to dashboard Cite

Cardiac remodeling occurs frequently in chronic kidney disease patients and affects quality of life and survival. Current treatment options are highly inadequate. As kidney function declines, numerous metabolic pathways are disturbed. Kidney and heart functions are highly connected by organ crosstalk. Among others, altered volume and pressure status, ischemia, accelerated atherosclerosis and arteriosclerosis, disturbed mineral metabolism, renal anemia, activation of the renin-angiotensin system, uremic toxins, oxidative stress and upregulation of cytokines stress the sensitive interplay between different cardiac cell types. The fatal consequences are left-ventricular hypertrophy, fibrosis and capillary rarefaction, which lead to systolic and/or diastolic left-ventricular failure. Furthermore, fibrosis triggers electric instability and sudden cardiac death. This review focuses on established and potential pathophysiological cardiorenal crosstalk mechanisms that drive uremia-induced senescence and disease progression, including potential known targets and animal models that might help us to better understand the disease and to identify novel therapeutics.

show abstract

Section: Pathology and Pathophysiology Of The Cardiorenal Syndromementioning

confidence: 99%

Cardiac Remodeling in Chronic Kidney Disease

Kaesler

Babler

Floege

et al. 2020

Toxins

100

View full text Add to dashboard Cite

show abstract

“…Left ventricular hypertrophy is seen in up to 72% of adult patients with CKD and ESRD and is also seen in children with ESRD (3–6). The prevalence of LVH is increased even in the early stages of CKD and the frequency increases progressively as renal function decreases (4,7).…”

Section: Left Ventricular Hypertrophy (Lvh) In Chronic Kidney Diseasementioning

confidence: 99%

NON‐CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Hypertrophy and Fibrosis in the Cardiomyopathy of Uremia—Beyond Coronary Heart Disease

Gross¹,

Ritz

2008

Seminars in Dialysis

148

131

View full text Add to dashboard Cite

Cardiac disease is the leading cause of death in uremic patients. In contrast to previous opinion, coronary events account for a relatively small proportion of cardiac deaths, the most common causes being sudden death and heart failure. Against this background the current text will discuss noncoronary cardiac pathology, specifically the pathogenesis and the morphological findings caused by (pathological) cardiac hypertrophy, cardiac interstitial fibrosis and microvascular disease.

show abstract

“…Left ventricular hypertrophy (LVH) has been reported in up to 72% of adults and children with end-stage renal disease (ESRD) (Johnstone et al, 1996;Levin et al, 1996;Mitsnefes et al, 2000;Rasic et al, 2004;Shin et al, 2007). Extensive studies have been performed to identify factors contributing to uremic cardiomyopathy in CKD patients, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems and hemodynamic alterations, as well as hypertension (Gross and Ritz, 2008;Vlahakos et al, 1997).…”

Section: Introductionmentioning

confidence: 99%

Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK/UCP2 signaling pathway

Yang

Nie

et al. 2015

Toxicology Letters

View full text Add to dashboard Cite

Left ventricular hypertrophy and risk factors for its development in uraemic patients

Abstract: Modification of existing risk factors in uraemic patients could contribute to prevention and treatment of LV hypertophy and thus reduce cardiovascular morbidity and mortality.

Cited by 13 publications

References 22 publications

Cardiac Remodeling in Chronic Kidney Disease

Cardiac Remodeling in Chronic Kidney Disease

NON‐CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Hypertrophy and Fibrosis in the Cardiomyopathy of Uremia—Beyond Coronary Heart Disease

Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK/UCP2 signaling pathway

Contact Info

Product

Resources

About